Últimas noticias sobre Bicara Therapeutics (NASDAQ:BCAX) Bolsa

BICARA THERAPEUTICS INC

Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Bicara Therapeutics Inc

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.37%</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and raised the price target from $24 to $25 on April 30, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) on Friday announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">latest PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="882" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114.png" alt="" class="wp-image-943187" style="width:620px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091603/image-114-768x733.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.10%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Monday, Merck reported positive topline results from the first two Phase 3 CORALreef trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="857" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115.png" alt="" class="wp-image-943188" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115.png 857w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091645/image-115-768x746.png 768w" sizes="(max-width: 857px) 100vw, 857px" /></a></figure>
<h3 class="wp-block-heading">GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.88%</li>
<li>Oppenheimer analyst Rupesh Parikh maintained an Outperform rating and raised the price target from $87 to $93 on Feb. 13, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Canaccord Genuity analyst Susan Anderson maintained a Buy rating and increased the price target from $93 to $100 on Feb. 7, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: GSK and Spero Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>), on May 28, announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest GSK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="863" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116.png" alt="" class="wp-image-943189" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116.png 863w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116-300x291.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09091720/image-116-768x746.png 768w" sizes="(max-width: 863px) 100vw, 863px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Dividends

Price Target

Analyst Ratings

ARVN

SPRO

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Maxim Group analyst Allen Klee reinstates ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) with a Buy and announces $20 price target.

Initiation

ARBB

Maxim Group Reinstates Buy on ARB IOT Group, Announces $20 Price Target

WIIM

ELEV

Elevation Oncology shares are trading higher after the company announced it entered into a definitive merger agreement with Concentra Biosciences.

Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) (&quot;Nuwellis&quot; or the &quot;Company&quot;), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the pricing of a public offering of 406,755 shares of its common stock (&quot;Common Stock&quot;), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 43,478,259 shares of Common Stock and Series B Warrants to purchase up to 14,492,753 shares of Common Stock.
The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants, and the public offering price per pre-funded warrant and accompanying warrants is $0.2999 per pre-funded warrant and accompanying warrants. Nuwellis expects to use the net proceeds from the offering for working capital and general corporate purposes, including possible acquisition activity.
Each pre-funded warrant has an exercise price of $0.0001 per pre-funded warrant, and is immediately exercisable until such pre-funded warrant is exercised in full. Each of the Series A Warrants and Series B Warrants has an exercise price of $0.30, and will be exercisable for a period of five years following the receipt of stockholder approval, as required by the applicable rules and regulations of Nasdaq.&nbsp; The Series A Warrants will contain a one-time reset of the exercise price in the event that the Company implements a reverse stock split to the greater of: (i) 20% of the combined public offering price per share of Common Stock and accompanying warrants in this offering and (ii) the lowest daily volume weighted average price for the five trading days immediately following the date of the implementation of a reverse stock split. The Series B Warrants will include a zero cash exercise option allowing holders of a Series B Warrant the right to receive, without payment of any additional cash to the Company, an aggregate number of shares equal to the number of shares of Common Stock that would be issuable upon a cash exercise of such Series B Warrant.
Ladenburg Thalmann &amp; Co. Inc. is acting as sole book-running manager in connection with the offering.
The offering is expected to close on or about June 10, 2025, subject to customary closing conditions.

Offerings

NUWE

Nuwellis Prices Public Offering Of 406,755 Common Shares And ~14M Pre-Funded Warrants With Series A And B Warrants At $0.30 Per Unit

Goldman Sachs analyst Leah Jordan maintains Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) with a Sell and lowers the price target from $27 to $25.

Goldman Sachs Maintains Sell on Kraft Heinz, Lowers Price Target to $25

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near our key level of 600.51. For the bulls, an initial move higher toward 601.22 would be constructive. Should buyers maintain strength above this mark, we'll be watching for a move toward 602.37. Holding above 602.37 could set the stage for an advance to 603.38. If momentum persists, the high bull target today is 604.45.&nbsp;
Should 600.51 fail to act as a firm support level, we anticipate sellers testing the 599.24 zone. A break below there could bring 598.04 into play. If downside pressure accelerates, a test of deeper support at 596.57 is expected. On a strong selloff, the low bear target for today would be 595.14.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is auctioning around the 530.70 level this morning. Bulls will want to see price sustained above 530.70 with the next upside objective at 532.52. If buyers continue to lead, we would look for a push into 533.70. A strong upside session could open the door for a test of 534.60. The high bull target for QQQ sits at 535.30.&nbsp;
If buyers cannot defend 530.70, watch for bears to attempt a move down toward 528.44. Further weakness could target 527.03. If momentum stays with the sellers, a test of 525.19 is likely. Should the bears control the session, the low bear target is 523.91.
Apple Inc. ( AAPL)
Apple is currently auctioning near 205.54. Bulls will aim to defend this level and look for a rotation up toward 206.55. Continued bullish action could lift price toward 207.18. Should momentum strengthen further, we would expect a test of the high bull target at 207.93.&nbsp;
If 205.54 breaks during regular trading hours, bears may drive the auction lower toward 204.33. Increased selling could pressure price down to 203.48. If this area fails to hold, 202.29 becomes the next key level. A decisive breakdown could take Apple to the low bear target of 200.53.
Microsoft Corp. (MSFT)
Microsoft is currently trading near 469.28. Bulls would like to see price holding firmly above 469.94 with potential to advance toward 470.77. Holding this level could attract more buyers and lead to an upside target of 472.11. Continued strength could result in a test of the high bull target at 472.91.&nbsp;
Failure to hold 469.28 may invite sellers to test 468.61. If this level is lost, watch for a move lower to 467.65. Should selling persist, 466.44 becomes the next downside focus. On a full bearish drive, today's low bear target is 464.70.
NVIDIA Corporation (NVDA)
NVIDIA is currently auctioning near 142.35. Bulls will want to see an early push toward reclaiming 144.21 and establishing it as support. If successful, buyers may look to press into 145.61. Sustained strength could then lead to 147.06. The high bull target for NVIDIA today is 148.52.&nbsp;
Should 142.35 give way, bears will likely press down to 141.21. If this level is breached, we expect sellers to target 140.28. Continued downside action could drive a test of 139.42. If selling intensifies, the low bear target for the session is 138.55.
Alphabet Inc Class A (GOOGL)
Alphabet is currently trading around 175.12. Bulls will want to see price climb and hold above 176.23. If buying remains steady, an advance toward 177.28 is likely. Continued bullish momentum could carry the auction to the high bull target at 179.15.&nbsp;
If 175.12 cannot hold, expect sellers to test 174.01. Should this level break down, 172.28 will likely be the next area of interest for the bears. If the downside persists, we are targeting a move toward the low bear target at 171.14.
Meta Platforms Inc (META)
Meta is currently trading near the 699.93 level. Bulls will be aiming to keep price above this mark with a move toward 704.07 on deck. If the bulls remain in control, the next level of interest would be 708.06. A sustained rally could take the auction to the high bull target at 712.14.&nbsp;
If 699.93 fails to hold, bears may take the opportunity to test 695.62. A break lower would set sights on 692.10. If weakness deepens, look for sellers to drive the auction toward the low bear target at 689.09.
Tesla Inc. (TSLA)
Tesla is auctioning around 290.47. Bulls will want to see price break above 293.21 and hold. Continued buying could propel the stock to 294.60. Should bullish momentum accelerate, a test of 296.44 is in view. The high bull target for today is 298.28.&nbsp;
If support at 290.47 breaks, watch for sellers to challenge 288.80. If selling intensifies, 286.34 becomes the next key level. Continued downside flow could lead to a move toward 283.95. On strong bearish momentum, the low bear target is 281.32.
Final Word:&nbsp;
The economic calendar is light today with April Final Wholesale Inventories and Trade Sales due at 10:00 AM ET, followed by the NY Fed 1-Year Inflation Expectations at 11:00 AM ET. With no major market-moving data scheduled, traders should remain alert for unexpected headlines or geopolitical developments that could spark volatility.&nbsp;
In this type of environment, price action will likely be more technically driven. Patience and precision will be key. Manage risk carefully and let the market reveal its hand before getting too aggressive. Wishing everyone a focused and successful trading session!
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it's published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

Tech

How To Trade SPY And Top Tech Stocks Using Technical Analysis

SOGP

Sound Group shares are trading higher after the company announced a $4 million stock buyback.

RSLS

ReShape Lifesciences shares are trading lower after the company announced the pricing of an offering of 1,054,604 shares at $2.50 per share.

Strategic acquisition enhances supply chain trading capabilities and market presence
SHANGHAI, June 9, 2025 /PRNewswire/ -- Nisun International Enterprise Development Group Co., Ltd ("Nisun International" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>), a technology-driven financing solutions provider and a technology and industry-driven integrated supply chain services provider, today announced a major expansion into the edible oil trading sector through its newly acquired subsidiary Zhetai (Tianjin) Trading Co., Ltd. ("Zhetai Tianjin"), a leading edible oil trading company in Northern China.
Zhetai Tianjin, specializes in the centralized procurement, storage, refining, logistics, and distribution of edible oils, including soybean oil, rapeseed oil, and palm oil. The company expects to generate RMB 3 billion (approximately USD 415 million) in revenue from its edible oil business in 2025, leveraging its robust market position and operational strengths.
Headquartered in the Tianjin Binhai Free Trade Zone, Zhetai Tianjin is recognized as a national-scale enterprise and a leader in Northern China's edible oil sector. It operates several established brands, including "Jiran," "Boxin," "Bohai Bian," and "Jixin," which are distributed across 11 provinces in China. Strategic partnerships with industry leaders such as COFCO, Sinograin, Beijing Grain Group, Louis Dreyfus, and Cargill ensure product quality and supply chain stability.

Guidance

NISN

Nisun International Announces Strategic Acquisition Of Zhetai Tianjin, A Leading Northern China Edible Oil Trader Projected To Generate ~$415M Revenue In 2025; Financial Terms Of Transaction Not Disclosed

Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, acquired an industrial property located in Los Angeles, California on June 6, 2025 for a purchase price of approximately $10.0 million.
The property consists of one industrial flex building containing approximately 34,000 square feet on 1.5 acres. The property is at 11100 Hindry Avenue, west of I-405 and adjacent to Los Angeles International Airport, and provides two dock-high and five grade-level loading positions. The property is 100% leased to four tenants all of which expire by September 2028 and the estimated stabilized cap rate is 6.4%.
Estimated stabilized cap rates are calculated as annualized cash basis net operating income stabilized to market occupancy (generally 95%) divided by total acquisition cost. Total acquisition cost includes the initial purchase price, the effects of marking assumed debt to market, buyer&#39;s due diligence and closing costs, estimated near-term capital expenditures and leasing costs necessary to achieve stabilization.
Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey, Los Angeles, Miami, San Francisco Bay Area, Seattle and Washington, D.C.

TRNO

Terreno Realty Acquires Industrial Property In Los Angeles, California For Purchase Price Of About $10M

SNPX

Synaptogenix shares are trading higher after the company announced it launched a $100 million AI Token treasury strategy focused on Bittensor with a $10 million initial acquisition in TAO.

Space-tech startup <a href="https://orbitt.space/">Orbitt Space</a> has secured $1 million in a pre-seed funding round. Pi Ventures headed the investor's list for the Ahmedabad, India firm, followed by IIMA Ventures. Orbitt will use the capital to accelerate the design and development of its proprietary electric propulsion and avionics systems for ultra-low Earth orbit, or ULEO, the transition zone below 155 miles altitude.
Founders Christopher Parmar and Anupam Kumar worked as scientists and engineers for the Indian Space Research Organization, which manages and develops India's space program. It's currently planning orbital missions targeting Venus, Mars and the moon, with a manned moon mission to be scheduled by 2040.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Wall Street's Missing This AI Surgical Tech — You Don't Have To.<a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution"> Invest from $350.</a></li>
</ul>
ULEO is a largely untapped orbital layer due to high atmospheric drag and fuel constraints. Satellites capable of navigating this realm have potentially lucrative applications in communications and weather imaging. Orbitt wants to build spacecraft that overcome these headwinds with air-breathing electric propulsion systems that use residual atmospheric gases as propellants. Parmar and Kumar believe their proprietary tech will allow satellites to remain sky bound in this space layer for five to seven years.&nbsp;
The satellite traffic jam in low Earth orbit, or LEO, the zone up to 1,240 miles, is reaching critical limits. The European Space Agency <a href="https://www.sdo.esoc.esa.int/environment_report/Space_Environment_Report_latest.pdf">warns</a> that over 40,000 objects are being tracked in this layer, as well as 1.2 million smaller debris fragments. Collision danger is increasing exponentially in these crowded skies, risking destruction of expensive systems and the potential for debris to hit the ground before it burns up.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
Parmar <a href="https://www.apnnews.com/orbitt-space-raises-1m-funding-led-by-pi-ventures-to-pioneer-air-breathing-electric-propulsion-for-ultra-low-earth-orbit-satellites/">touted</a> the benefits of the startup, saying, "ULEO is the cleanest and most strategic orbit around Earth, yet it has remained inaccessible until now. Our electric propulsion system will change that, enabling satellites to operate longer missions at low altitudes while delivering advanced imaging and data capabilities without contributing to orbital pollution. With this funding, we take our first step toward making sustainable, fuel-free satellite operations a reality."
In the first stage, Orbitt wants to build a team of scientists and engineers, and test a prototype to validate the space tech. IIMA Ventures has seeded <a href="https://www.linkedin.com/company/orbitt-space/posts/">two other</a> Ahmedabad startups and there are no guarantees that funding will continue if more lucrative space tech emerges from their investments.
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Orbitt wants to demonstrate the tech's potential through in-orbit demonstrations in later phases and roll out commercial production of a ULEO satellite system. However, the startup space chasing this segment has grown more crowded, with UK's <a href="https://www.neworbit.space/">NewOrbit Space</a> and India's <a href="https://bellatrix.aero/">Bellatrix Aerospace</a> well along in their research, development and potential production.&nbsp;
NewOrbit is testing its tech in ground-based vacuum chambers but has yet to schedule an in-orbit demonstration. It was awarded a <a href="https://activities.esa.int/4000144449">contract</a> from the European Space Agency last year to "advance development of air-breathing thrusters and cathodes." Closer to Orbitt's home, Bellatrix <a href="http://bellatrix.aero/updates/unveiling-project-200">showed off</a> its propulsion tech at the Bengaluru Space Expo 2024 last September and hopes to launch its first satellite by 2026.
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Image: Shutterstock

Orbitt Space's Air-Breathing Engine Raises $1M to Conquer Ultra-Low Earth Orbit

It's been smooth sailing for Carnival Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) in recent months, while rival Norwegian Cruise Line Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) is still <a href="https://www.benzinga.com/quote/NCLH/news">navigating choppy waters</a>.
However, according to JPMorgan analyst Matthew R. Boss, 2026 could be the year Norwegian flips the script.
<h2 class="wp-block-heading">What&#8217;s Been Driving Carnival&#8217;s 20% Bullish Streak?</h2>
Carnival stock has surged over 20% in the past month and is up nearly 47% year-over-year. The company continues outperforming thanks to strong booking trends, disciplined pricing, and a Europe-focused strategy that's paying off. CEO Josh Weinstein is steering Carnival with a clear focus on yield optimization, margin expansion, and cost discipline. The launch of Celebration Key in the third quarter and over six quarters of margin improvement are fueling bullish sentiment.
Boss highlights Carnival's balance sheet progress as another catalyst, noting the company could hit its investment-grade leverage target ahead of schedule &#8211; potentially unlocking share buybacks or dividends down the line.
Read Also: <a href="https://www.benzinga.com/general/travel/25/05/45680686/premium-travel-demand-gives-airlines-hotels-and-cruises-an-edge-in-2025-goldman-sachs">Premium Travel Demand Gives Airlines, Hotels And Cruises An Edge in 2025: Goldman Sachs</a>
<h2 class="wp-block-heading">Down, But Not Out &#8211; What&#8217;s Behind Norwegian&#8217;s 40% Potential Upside?</h2>
Meanwhile, Norwegian shares have lagged, down over 24% year-to-date despite a 10% rebound in the last month. Still, JPMorgan is sticking with its Overweight rating and a $28 price target &#8211; suggesting over 40% upside from here. The firm hosted Norwegian's top execs in Miami and came away with cautious optimism.
CFO Mark Kempa acknowledged soft demand in the third quarter, especially for longer European itineraries, but emphasized a return to healthy booking levels. More importantly, Norwegian sees a clear path to recapturing occupancy and yield growth by FY26. Management aims for 104.9% occupancy next year &#8211; well above current levels &#8211; paired with a greater mix of higher-yielding 7-day cruises.
Luxury brands Regent and Oceania are other long-term levers, with new leadership aiming to boost margins to peer levels. Norwegian is tightening up behind the scenes on the cost front without touching the guest experience &#8211; an approach that&#8217;s already lifting satisfaction scores.
Carnival may be the current winner of the cruise wars, but Norwegian isn't out of the race. JPMorgan sees a compelling setup for long-term investors willing to wait for smoother seas in 2026.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45572655/bofa-sees-mixed-signals-in-leisure-sector-highlights-strength-in-premium-travel-and-cruise-stability">Bank Of America Sees Mixed Signals In Leisure Sector, Highlights Strength In Premium Travel And Cruise Stability</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Travel

NCLH

Cruise Wars: Carnival Rides Momentum, While Norwegian Plays The Long Game

JBIO

Jade Biosciences shares are trading higher after the company a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy

Goldman Sachs analyst Leah Jordan downgrades Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Neutral to Sell and lowers the price target from $26 to $21.

Downgrades

Goldman Sachs Downgrades Conagra Brands to Sell, Lowers Price Target to $21

Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>, the "Company"))), a leading gaming accessories brand, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one right ("Right") for each outstanding share of common stock. The record date for such dividend distribution is June 23, 2025.
The adoption of the Rights Plan is intended to enable all stockholders to realize the full potential value of their investment in the Company and protect the Company and its stockholders from the actions of third parties that the Board determines are not in the best interests of the Company and its stockholders. In addition, the Rights Plan provides the Board with time to make informed, deliberate decisions that are in the best long-term interests of the Company and its stockholders. The Rights Plan will expire, without any further action being required to be taken by the Board, on June 9, 2026.
The Rights Plan is similar to stockholder rights plans adopted by other publicly-held companies. Under the Rights Plan, the Rights generally would become exercisable only if a person or group acquires beneficial ownership of 10% or more of the Company's common stock in a transaction not approved by the Board. In that situation, each holder of a Right (other than the acquiring person or group, whose Rights will become void and will not be exercisable) will be able to purchase, upon payment of the then-current exercise price, a number of shares of the Company's common stock having a market value of twice such price. In addition, if the Company is acquired in a merger or other business combination after an acquiring person acquires 10% or more of the Company's common stock, each holder of the Right would thereafter be able to purchase, upon payment of the then-current exercise price, a number of shares of common stock of the acquiring company having a market value of twice such price. The acquiring person or group would not be entitled to exercise these Rights.
The Rights Plan includes a qualifying offer clause, which provides stockholders with the potential ability to call a special meeting for purposes of exempting a pending offer that meets certain qualifying criteria.
The Rights Plan has not been adopted in response to any specific takeover bid or other proposal to acquire control of the Company and is not intended to deter offers that are fair and otherwise in the best interests of the Company and its stockholders.
Stockholders who currently beneficially own 10% or more of the Company's outstanding common stock will not trigger any penalties under the Rights Plan so long as they do not acquire beneficial ownership of any additional shares of common stock on a cumulative basis, subject to certain exceptions as described in the Rights Plan.

Management

TBCH

Turtle Beach Board Approves Limited Duration Stockholder Rights Plan To Protect Shareholder Value And Declares Dividend Of One Right Per Share, Effective June 23, 2025

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">104.25</td>
<td align="right">0.54</td>
<td align="right">0.52</td>
<td>3.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">83.69</td>
<td align="right">0.28</td>
<td align="right">0.33</td>
<td>44.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.10</td>
<td align="right">0.74</td>
<td align="right">0.31</td>
<td>105.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.41</td>
<td align="right">0.13</td>
<td align="right">0.25</td>
<td>26.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">145.23</td>
<td align="right">0.30</td>
<td align="right">0.20</td>
<td>4.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.34</td>
<td align="right">0.15</td>
<td align="right">0.18</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.89</td>
<td align="right">0.11</td>
<td align="right">0.12</td>
<td>611</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.51</td>
<td align="right">0.13</td>
<td align="right">0.09</td>
<td>4.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.91</td>
<td align="right">0.03</td>
<td align="right">0.07</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.70</td>
<td align="right">0.01</td>
<td align="right">0.01</td>
<td>4.0K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">211.91</td>
<td align="right">-0.26</td>
<td align="right">-0.13</td>
<td>3.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 9, 2025

Singular focus on Bittensor (TAO), the leading AI token by adoption and market capitalization
James Altucher to lead TAO token strategy initiatives
Planned initial acquisition of $10 million in TAO equates to over two times the Company's&nbsp; current market capitalization; total acquisition target of $100 million
NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altucher will lead a TAO-based revenue generation strategy targeting staking yield and token appreciation.
Synaptogenix plans to acquire $10 million in TAO tokens initially, which amounts to over two times the Company's current market valuation. The Company's strategy is targeted to acquire $100 million of TAO tokens. The initial acquisition will be funded by the Company's significant cash reserves and well-capitalized balance sheet.

Synaptogenix Launches $100M AI Token Treasury Strategy Focused On Bittensor (TAO) With $10M Initial Acquisition Led by Crypto Expert James Altucher

Goldman Sachs analyst James Yaro downgrades General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) from Buy to Neutral and lowers the price target from $68 to $58.

Goldman Sachs Downgrades General Mills to Neutral, Lowers Price Target to $58

Health Care

Press Releases

General

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Earnings

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Comments

Bicara Therapeutics

Noticias

Últimas noticias sobre Bicara Therapeutics (NASDAQ:BCAX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL